original ) (raw )Cost Effectiveness Analysis of Disease-Modifying Antirheumatic Drugs in Rheumatoid Arthritis. A Systematic Review Literature
Manathip Osiri
International Journal of …, 2011
View PDFchevron_right
Cost Utility of Tumour Necrosis Factor-α Inhibitors for Rheumatoid Arthritis
Rashid Kazerooni , Anthony Morreale
PharmacoEconomics, 2012
View PDFchevron_right
Cost effectiveness analysis of disease modifying antirheumatic drugs in rheumatoid arthritis
Mariangela Manfredi , Maurizio Benucci , P. Puttini
Rheumatology International, 2007
View PDFchevron_right
Cost Effectiveness of TNF- Inhibitors in Rheumatoid Arthritis
Maurice Zarb-Adami , Anthony Inglott
International Journal of Inflammation, 2013
View PDFchevron_right
An Overview of Economic Evaluations for Drugs Used in Rheumatoid Arthritis: Focus on Tumour Necrosis Factor?? Antagonists
roberta ara
Drugs, 2005
View PDFchevron_right
Critical appraisal of pharmacoeconomic studies comparing TNF-α antagonists for rheumatoid arthritis treatment
J. Puig-junoy
Expert Review of Pharmacoeconomics & Outcomes Research, 2007
View PDFchevron_right
A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness
Amanda Burls
Health technology assessment (Winchester, England), 2006
View PDFchevron_right
Cost-effectiveness of TNF inhibitors vs synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: a Markov model study based on two longitudinal observational studies
T. Uhlig
Rheumatology (Oxford, England), 2015
View PDFchevron_right
Cost-Effectiveness of Sequential Therapy with Tumor Necrosis Factor Antagonists in Early Rheumatoid Arthritis
Andrew Davies , Mary Cifaldi
The Journal of Rheumatology, 2008
View PDFchevron_right
Randomised controlled trial of tumour necrosis factor inhibitors against combination intensive therapy with conventional disease-modifying antirheumatic drugs in established rheumatoid arthritis: the TACIT trial and associated systematic reviews
Fowzia Ibrahim
Health technology assessment (Winchester, England), 2014
View PDFchevron_right
An Overview of Economic Evaluations for Drugs Used in Rheumatoid Arthritis
Alan Brennan
Drugs, 2005
View PDFchevron_right
Modelling the cost effectiveness of TNF- antagonists in the management of rheumatoid arthritis: results from the British Society for Rheumatology Biologics Registry
Alan Brennan
Rheumatology, 2007
View PDFchevron_right
Cost-effectiveness of abatacept, rituximab, and TNFi treatment after previous failure with TNFi treatment in rheumatoid arthritis: a pragmatic multi-centre randomised trial
Hein Bernelot Moens , E. Brouwer
Arthritis Research & Therapy, 2015
View PDFchevron_right
Cost-effectiveness modelling of biological treatment sequences in moderate to severe rheumatoid arthritis in France
Eric Boccard
Rheumatology, 2010
View PDFchevron_right
Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a tumour necrosis factor inhibitor: a systematic review and economic evaluation
Olalekan Uthman
Health Technol Assess, 2011
View PDFchevron_right
Cost-effectiveness modeling of abatacept versus other biologic agents in DMARDS and anti-TNF inadequate responders for the management of moderate to severe rheumatoid arthritis
Carter Thorne
Clinical Rheumatology, 2008
View PDFchevron_right
Cost evaluation of novel therapeutics in rheumatoid arthritis (CENTRA):A decision analysis model
RITA JAIN
Seminars in Arthritis and Rheumatism, 1996
View PDFchevron_right
The psoriatic arthritis cost evaluation study: a cost-of-illness study on tumour necrosis factor inhibitors in psoriatic arthritis patients with inadequate response to conventional therapy
Alberto Di Mase
Rheumatology, 2008
View PDFchevron_right
Pharmacoeconomics of long-term treatment of rheumatoid arthritis
Peter Tugwell
Expert Opinion on Pharmacotherapy, 2002
View PDFchevron_right
Cost-Effectiveness Analysis of Biopharmaceuticals for Treating Rheumatoid Arthritis: Infliximab, Adalimumab, and Etanercept
Ahmad Gholami
BioMed Research International, 2021
View PDFchevron_right
Differences in annual medication costs and rates of dosage increase between tumor necrosis factor-antagonist therapies for rheumatoid arthritis in a managed care population
Saurabh Rai
Clinical Therapeutics, 2009
View PDFchevron_right
Pharmacoeconomic evaluation of treatment effectiveness with selected biologic treatment in rheumatoid arthritis therapy
Sławomir Jeka
Reumatologia, 2018
View PDFchevron_right
Impact of medical practices on the costs of management of rheumatoid arthritis by anti-TNFα biological therapy in France
Marie-christine Woronoff-lemsi
Joint Bone Spine, 2005
View PDFchevron_right
Personal non-commercial use only. The Journal of RheumatologyJ Rheumatol First Release
vibeke strand
2020
View PDFchevron_right
Effectiveness and Costs of TNF-Alpha Blocker Use for Patients with Rheumatoid Arthritis
Ahmad ainun Naim
American health & drug benefits, 2013
View PDFchevron_right
Cost effectiveness of adding leflunomide to a 5-year strategy of conventional disease-modifying antirheumatic drugs in patients with rheumatoid arthritis
vibeke strand
Arthritis & Rheumatism, 2002
View PDFchevron_right
Systematic literature review on economic implications and pharmacoeconomic issues of rheumatoid arthritis
Lucia D'Angiolella
Clinical and experimental rheumatology
View PDFchevron_right
Effectiveness of tumor necrosis factor inhibitors in rheumatoid arthritis in an observational cohort study: Comparison of patients according to their eligibility for major randomized clinical trials
Joachim Listing
Arthritis & Rheumatism, 2006
View PDFchevron_right
Alternative tumour necrosis factor inhibitors (TNFi) or abatacept or rituximab following failure of initial TNFi in rheumatoid arthritis: the SWITCH RCT
Christopher McCabe
Health technology assessment (Winchester, England), 2018
View PDFchevron_right
Modelling the cost effectiveness of TNF-α inhibitors in the management of rheumatoid arthritis: results from the British Society for Rheumatology Biologics Registry
Alan Brennan
2006
View PDFchevron_right
One-year direct costs of biological therapy in rheumatoid arthritis and its predictive factors: data from the Moroccan RBSMR registry
Ihsane Hmamouchi
2021
View PDFchevron_right